Quote this publication Share Print

DESCOVY (emtricitabine, tenofovir alafenamide), antiretroviral combination

VIROLOGY - NEW MEDICINAL PRODUCT
Opinions on drugs - Posted on Jul 12 2017

Reason for request

Inclusion

No clinical benefit demonstrated for this second-line treatment in the treatment of HIV infection.

  

  • DESCOVY, in combination with other antiretrovirals, has the Marketing Authorisation in the treatment of adults and adolescents (aged 12 years and older, weighing at least 35 kg) infected with type 1 human immunodeficiency virus (HIV-1).
  • In adults, it is an alternative to TRUVADA (emtricitabine, tenofovir disoproxil fumarate).
  • In adolescents and patients with moderate renal failure (estimated creatinine clearance ≥ 30 mL/min), it is a therapeutic option only in cases in which it is not possible to prescribe first-line medicinal products that are not associated with a risk of kidney and bone damage.
  • It must be used alongside monitoring of renal function, calcium and phosphorus metabolism, and lipid parameters.

 

 


Clinical Benefit

Substantial

-


Clinical Added Value

no clinical added value

-


Therapeutic use

-

Contact Us

Évaluation des médicaments